All News

Biomarker trajectories over 5 years in study participants with AD show steeper rises in pTau217, NfL, and amyloid burden among those with obesity, highlighting risk factor relevance.

The landmark global policy recognizes obesity as chronic disease requiring lifelong care, warns of inequitable access and proposes 3-pillar strategy targeting prevention, screening, treatment.

Emory's Clevenger discusses the neurotransmitter dysregulation behind agitation in AD and why memory-focused care doesn't address behavioral symptoms.

Psychiatric comorbidities affect 25% of AD patients. Here, a check list on when to screen, when to refer, and how to prevent accumulated psychological burden in primary care.

New safety and biomarker results from MK-2214 and MK-1167 advance Merck’s dual approach to Alzheimer therapy.

Two-thirds of participants experienced clinically meaningful response within 3 months; effects sustained through 12 months with mild adverse event profile.

New data reveals evolocumab significantly reduces long-term major cardiovascular event risks in ASCVD patients, enhancing treatment strategies for better outcomes.

Former CBER chief calls claims "misrepresentation." ID experts Offit and Osterholm criticize timing ahead of CDC advisory committee meeting next week.

Clevenger reviews survey findings behind the recent report "The Agitation Blindspot in Alzheimer’s Care."

A regular focus on mental heatlh during follow-ups with patients who have atopic dermatitis can be integrated simply with a few thoughtful questions.